The Drug Enforcement Administration (DEA) has proposed making permanent some COVID-19 rules for prescribing controlled medications via telemedicine. The rules would allow for Schedule III medications (e.g., buprenorphine) to be prescribed for a 30-day supply, with no prior in-person consultation, but would require an in-person visit for a refill. Section II medications (e.g., methadone) would require an in-person visit prior to a prescription.
Comments are due within 30 days of the February 24 release date. See DEA Announces Proposed Rules for Permanent Telemedicine Flexibilities.
Browse for More